Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the...

Full description

Bibliographic Details
Main Authors: Monika Conchon, Carla Maria Boquimpani de Moura Freitas, Maria Aparecida do Carmo Rego, José Wilson Ramos Braga Junior
Format: Article
Language:English
Published: Elsevier 2011-01-01
Series:Revista Brasileira de Hematologia e Hemoterapia
Subjects:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug toxicity
Drug interactions
Gastrointestinal tract
Drug resistance, neoplasm
Pyrimidines
Interferonalpha
Piperazines
Clinical Trial
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012

Similar Items